Zevra Therapeutics, Inc. - Common Stock (ZVRA)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 6, 2026Investment Snapshot
- Trading 7% below Graham Number — thin margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 55.5% — good return on equity
Zevra Therapeutics, Inc. - Common Stock (ZVRA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $718 million . Key value metrics: P/E ratio 5.9, P/B ratio 3.30, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Zevra Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Zevra Therapeutics, Inc. - Common Stock (ZVRA) is trading 7% below its Graham Number of $12.95, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 5.9x.
On financial health, ZVRA shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 55.5% (sector average: -20.1%).
StockPik's composite Value Score for ZVRA is 85/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ZVRA shows earnings growing at 179%.